149 related articles for article (PubMed ID: 12759578)
1. Advanced IgA nephropathy: to treat or not to treat?
Locatelli F; Pozzi M; Del Vecchio L; Pozzi C
Nephron Clin Pract; 2003; 93(4):c119-21. PubMed ID: 12759578
[No Abstract] [Full Text] [Related]
2. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy.
Rasche FM; Klotz CH; Czock D; Karges W; Muche R; Jehle PM; Mertz A; Keller F
Nephron Clin Pract; 2003; 93(4):c131-6. PubMed ID: 12759581
[TBL] [Abstract][Full Text] [Related]
3. Prognostic indicators and treatment of childhood IgA nephropathy.
Hogg RJ
Contrib Nephrol; 1995; 111():194-9; discussion 199-200. PubMed ID: 7758342
[No Abstract] [Full Text] [Related]
4. IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice.
Strippoli GF; Maione A; Schena FP; Tognoni G; Craig JC
Am J Kidney Dis; 2009 Jan; 53(1):5-8. PubMed ID: 19101396
[No Abstract] [Full Text] [Related]
5. Cohort study of advanced IgA nephropathy: efficacy and limitations of corticosteroids with tonsillectomy.
Sato M; Hotta O; Tomioka S; Horigome I; Chiba S; Miyazaki M; Noshiro H; Taguma Y
Nephron Clin Pract; 2003; 93(4):c137-45. PubMed ID: 12759582
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[TBL] [Abstract][Full Text] [Related]
7. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
8. [Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].
Pozzi C; Del Vecchio L; Locatelli F
G Ital Nefrol; 2002; 19(5):523-8. PubMed ID: 12439840
[TBL] [Abstract][Full Text] [Related]
9. [IgA nephropathy - prognostic factors and treatment].
Wieliczko M; Dylewska M
Wiad Lek; 2016; 69(5):707-710. PubMed ID: 28033590
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids in the treatment of IgA nephropathy: any light beyond the clouds of confusion?
Chan TM
Postgrad Med J; 2018 Jul; 94(1113):371-373. PubMed ID: 29891644
[No Abstract] [Full Text] [Related]
11. Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases.
Kobayashi Y; Fujii K; Hiki Y; Tateno S; Kurokawa A; Kamiyama M
Nephron; 1988; 48(1):12-7. PubMed ID: 3340251
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of steroid pulse therapy in patients with IgA nephropathy and impaired renal function].
Ikeuchi H; Hiromura K; Sakairi T; Yamashita S; Okajo J; Tomizawa T; Tamura S; Maeshima A; Kaneko Y; Kuroiwa T; Ueki K; Tsukada Y; Kawai H; Wakamatsu R; Nojima Y
Nihon Jinzo Gakkai Shi; 2008; 50(2):114-21. PubMed ID: 18421967
[TBL] [Abstract][Full Text] [Related]
13. [Mycophenolate mofetil in high risk IgA glomerulonephritis].
Frutos MA; López V; Alférez MJ; Aranda P
Nefrologia; 2005; 25(4):387-92. PubMed ID: 16231504
[TBL] [Abstract][Full Text] [Related]
14. Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
Donadio JV; Bergstralh EJ; Bibus DM; Grande JP
Clin J Am Soc Nephrol; 2006 Sep; 1(5):933-9. PubMed ID: 17699310
[TBL] [Abstract][Full Text] [Related]
15. Comparison of steroids and angiotensin receptor blockers for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T; Amemiya N; Ochi A; Tsuruta Y; Shimizu A; Itabashi M; Takei T; Uchida K; Nitta K
Am J Nephrol; 2011; 34(3):233-40. PubMed ID: 21778707
[TBL] [Abstract][Full Text] [Related]
16. Combination of pulse cyclophosphamide and steroids in crescentic IgA nephropathy.
Ramachandran R; Doddi P; Nandakrishna B; Nada R; Kumar V; Rathi M; Kohli HS; Jha V; Sakhuja V; Gupta KL
Int Urol Nephrol; 2015 Nov; 47(11):1917-8. PubMed ID: 26411427
[No Abstract] [Full Text] [Related]
17. The long-term efficacy and safety of immunosuppressive therapy on the progression of IgA nephropathy: a meta-analysis of controlled clinical trials with more than 5-year follow-up.
Tian L; Shao X; Xie Y; Wang L; Wang Q; Che X; Ni Z; Mou S
Expert Opin Pharmacother; 2015 Jun; 16(8):1137-47. PubMed ID: 25892092
[TBL] [Abstract][Full Text] [Related]
18. Combined immunosuppression in high-risk patients with IgA nephropathy?
Floege J; Eitner F
J Am Soc Nephrol; 2010 Oct; 21(10):1604-6. PubMed ID: 20829408
[No Abstract] [Full Text] [Related]
19. Predictors of Progression in IgA Nephropathy in Childhood.
Mizerska-Wasiak M; Małdyk J; Turczyn A; Cichoń-Kawa K; Rybi-Szumińska A; Wasilewska A; Bieniaś B; Zajączkowska M; Miklaszewska M; Pietrzyk J; Demkow U; Roszkowska-Blaim M; Pańczyk-Tomaszewska M
Adv Exp Med Biol; 2017; 955():65-73. PubMed ID: 27718216
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive therapy in patients with IgA nephropathy.
Peters HP; van den Brand JA; Berger SP; Wetzels JF
Neth J Med; 2015 Jul; 73(6):284-9. PubMed ID: 26228193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
